full comment requir non-u analyst conflict disclosur
pleas click link
initi outperform happi pay alpha
earli turnaround encourag thought forward post-manag call
sign progress long road ahead
struggl see realist upsid case lower target
sign green shoot
short-term pain long-term gain
post-cal rubraca beat build confid lower pt cash model
recap model updat
cut ep organ growth target short-cycl weak
est move higher better growth margin remain op
omidubicel pivot track eye nk program updat year-end
solid cloud pampacancha delay
look window margin inflect
set smooth
investor frustrat justifi chang need lower price target
post-cal model updat reduc pt spend
gain traction valuat keep us sp
attract entri point fundament still solid
price prior day market close estimate unless otherwis note
scratch surfac signific opportun
 anoth beat rais
stronger expect project track
 peripher vascular next leg growth
suppli logist drive big beat increas guidanc
zilu gmg data look good add valid durabl prior updat
solid start improv ss top-line growth
macro fundament backdrop intact fuel strong growth
buckl charg clinic potenti first data
stick
solid trend push result near top end full-year ffo outlook
volum challeng persist dmg sale look closer
pipelin updat move forward focu
strong track record execut reiter op
nda re-submiss time slip plan otherwis remain track
acceler invest trend drive better long-term growth target
in-lin result wait back half
clean quarter littl debat xyrem life-cycle need remain focu
larg line transit continu takeout headlin emerg
review model updat
result expect speedpay sale creat nois
ffo trend stabil larg deal could provid step-up though
solid result growth drive
pictur week volume
 of daili summari
 follow barrel global
oil trade scorecard
 wide open space room grow sub
continu strong busi momentum shoulder highlight
zero bolt pepsico gatorad situat
strip nois focus physic barrel
find research
insight www rbcinsightresearch com global research destin web contact capit market sale
repres access global research site use ipad app research
market data gbp financi data gbp
valu usd unless otherwis note
initi outperform happi pay alpha
alpha organ growth outlook one best within coverag univers
year compound-annual-growth-rate ep compound-annual-growth-rate similarli compel tailwind behind
growth larg structur balanc sheet net cash provid option
acquisit return perspect initi outperform
price target
initi outperform price target
view consensu estim low set ep
estim ahead respect
continu growth global aum on-going consolid regulatori pressur
like sustain high level growth
given competit backdrop think would surpris see
take-over approach group
earli turnaround encourag thought forward post-manag call
deliv better result guidanc expect
help uncertainti around risk downsid weigh share
clear progress long way go get past manufactur
challeng address high leverag rebuild growth stori earli
encourag pt model updat appli specul risk qualifi
rate
turnaround effort well underway year back-half weight
sequenti improv expect balanc year half
year ebitda guidanc million weight larg driven
oper improv smaller extent new launch revenu
though new launch revenu approv product importantli
also indic expect ebitda least doubl per
discuss manag gross margin could ramp back
rang next year million fda-rel complianc enhanc weigh
margin year normal ebitda trade
reason view given turnaround bull case remain link
take-out higher level
near-term focu remain remedi effort move
posit provid full year guidanc big step next big step get
past manufactur headwind progress fda action item relat
inspect continu major effort complet
valu usd unless otherwis note
mid-year compani regular dialogu fda agenc
expect return conduct full gmp inspect manag indic
expect anyth big fda even agenc suggest
improv somerset volum begun ramp back
sign progress long road ahead
believ guidanc show evid improv take hold
low-hand fruit harder work ahead believ market expect
may gotten ahead stock view manag tri keep
expect check posit long run pt remain
result in-line pre-announce revenu y/i
y/i organ adj ebitda y/i ep sourc
high-end pre-announce rang time
work capit lower capital-expenditure quarter help
guidanc show improv take holdth midpoint adnt
sale guidanc assum sale lower yet
ebitda commentari suggest higher
equiti incom guidanc suggest equal put
togeth suggest action taken core consolid busi
commerci oper least start take hold
turnaround multi-year hard work quick fix believ
attack low hang fruit commerci action lower premium freight
lower launch cost mostli stabil busi
focu remaind look improv period
continu focu oper execut commerci disciplin reduct
launch rightsiz ss optim period beyond
manag doesnt expect close peer margin gap
struggl see realist upsid case lower target
move past continu see downsid risk medium term growth
target valu creation strateg action board/manag less like
view puts/tak outlook see take
reflect conserv stanc growth limit temper enthusiasm
valu argument speak downsid support upsid limit
lower ebitda billion billion
billion put us street ebitda grow think overli
aggress adjust restasi face gener competit follow
intra-day note earn call instil confid statu quo
strateg messag thought call primari bull camp push-back
valu usd unless otherwis note
valu usd unless otherwis note
heard relat confid management/board review
opportun come sens urgenc note board held call
investor run proxi vote process/meet
known discuss mani came ahead push vote
propos link whether board actual take action action
would import question would will revisit
real movement skeptic
sign green shoot
difficult stretch report encourag start heel
improv segment life retir unit also
report bounce-back quarter particular strength life seen
fals start quarter show progress remain construct
share ahead expect continu traction turnaround effort
estim price target rais oper ep forecast
mainli factor upsid rais
oper ep forecast reflect better expens ratio
invest incom assumpt rais price target
still approxim end tangibl book valu per
signific upsid estim report oper ep
vs last year consider ahead estim
consensu expect upsid estim broad
base sever area biggest posit varianc gener insur
posit solid y/i improv gener insur accid year
combin ratio strong oper incom growth life unit posit
flow retir overal reserv releas improv insur
neg share buyback quarter weaken gener insur
premium new money invest yield life retir still
exist yield
short-term pain long-term gain
maintain op rate reflect inexpens valuat attract posit
within outsourc framework howev share could penalti box
follow light reduc ep
consensu ep target chang reset
oper outlook decemb investor day subsequ nudg
higher reflect balanc sheet action includ impact relat
weather well strateg action reduc estim
price target maintain op rate new ep
share steep discount peer compani histor
level although believ share could penalti box time
believ current pain point could compani better posit
valu usd unless otherwis note
valu usd unless otherwis note
go forward return double-digit ep growth within attract
chang see adj ep vs prior
bia mid-point/bett con new rang put ep
growth els continu expect legaci revenue growth
avendra/ameriprid synergi support debt
rel expect ep shortfal occur weather
client retent cost updat view
expect includ cent weather exit certain int
biz calendar time exit int agreement make sens view/
posit implic given gener posit return/
headwind repeat likewis invest retain business/
gener new import well
reduc estimates/target adj ep
pt unchang price-to-earnings multipl
mark anoth strong quarter outperform-r atkor
oper beat fuel posit electr raceway volum solid price
gain atkor expect stay price/cost posit compani
rel insul tariff/trade-frict fallout net leverag look
manag plan work year-end still see share
posit electr raceway volum price strength margin expans
drive upsid quarter guidanc boost atkor deliv solid
result beat estim oper line contribut
segment welcom posit quarter electr
raceway volum growth segment seen contract volum
past four quarter manag held view market activ
support growth expect inflect posit volum growth
manag qualit commentari custom give us
confid compani abil hit electr raceway volum
target mp volum contract quarter note
segment face tough comp includ larg secur
renew energi project atkor show price strategi remain
full forc gross price quarter price offset
commod freight cog inflat manag expect
price/cost posit move guidanc compani rais
ep adjust ebitda rang ahead consensu
respect midpoint expect atkor delev next
two quarter see room small bolt-on deal level increas
ep estim rais price target
valu usd unless otherwis note
valu usd unless otherwis note
plan good start oil product modestli
expect await recut guid pro forma ranger divestitur
appear good shape meet beat origin expect
capital-expenditure bit higher expect rig ramp mitig
spend
solid start strong start oil product trend
near high end fy guid expect delawar optim boe/
impact pad time result volum flat
consist prior expect growth pick back
new co-develop pad come on-line
effici gain make impact shift larger co-develop well
process improv led effici gain shorter cycl
time result greater capit alloc vs prev
firm would hold spend within budget
free cash flow gener move closer continu target free cash flow
gener note current strip price could begin earli
make headway portfolio optim follow million ranger
sale plan remain opportunist divestitur front
net acr non-op delawar posit next like candid
would also consid selling/swap certain orphan acreag block well
recent built-out water infrastructur
estim larg unchang oil product estim
mainli flow-through strong number cfp
estim price target increas
post-cal rubraca beat build confid lower pt cash model
report result rubraca sale beat st beat
driven earli eu sale see ad confid rubraca surprisingli
strong sale continu see clvss opportun prostat cancer
potenti first-mov advantag primari valu driver lower pt
lower project cash posit
add confid rubraca continu uptak oc mainten
initi launch eu report rubraca revenu vs st
st factset grow q/q sale link
note growth stem recent price increas mitig season
headwind march ex-u rubraca launch germani uk israel
sold ex-u us sale miss estim note quarter
neg impact season rebat gross-to-net impact
management confirm us demand growth quarter despit limit us revenu
growth specif season impact stem higher co-pay assist
cost gpo rebat govern rebat increas gross-to-net
vs updat financi model
reflect clvss recent financ remov project equiti rais
result reduct pt base decreas cash balanc
valu usd unless otherwis note
valu usd unless otherwis note
recap model updat
revenu ebitda modestli miss ffo/sh exceed expect new
mrr mw leas trail prior four-quart averag strong
comp grew sequenti par level guidanc
midpoint unchang revenu ebitda increas ffo/sh
decreas develop capital-expenditure
view revenu ebitda modestli miss ffo/sh exceed
expect new leas volum mrr mw sign trail prior
four-quart averag strong comp sequenti
par level manag guidanc midpoint unchang
revenu ebitda increas ffo/sh decreas develop
summari revenues/ebitda lower
y/i growth ffo/sh affo/sh compar
interconnect revenu increas y/i
estim revenues/ebitda previou
core ffo/shar previou
revenues/ebitda previou
core ffo/shar previou
dcp ebitda dcf exceed expect better logist
market result vs estim addit dcp continu drive cost lower
ad capac drive margin higher dcp better posit
address idr growth project come on-line cash flow grow balanc
sheet improv updat estim increas price target lower
logist market drive beat logist market ebitda beat
estim ngl pipelin volum exceed
estim stronger volum sand hill vs
pipelin vs optim dcp
increas sand hill capac capit outlay
segment also benefit permian ga differenti higher ga
market margin guadalup expect moder permian ga
growth project updat oconnor servic associ
bypass front rang texa express expans come on-line
gulf coast express on-line octob southern hill
expans on-line dcp expect add
process capac dj basin bighorn project
expect dcp exercis option acquir cheyenn connector
sweeni fraction late
valu usd unless otherwis note
valu usd unless otherwis note
cut ep organ growth target short-cycl weak
sector perform-r emerson segment oper miss
guidanc cut attribut increment shortfal across
commerci end market soft-spot includ upstream oil discret
autom southeast asia middl east respons manag
acceler restructur slow invest shore-up profit
see increment risk emerson ep target
cut ep guidanc softer short-cycl growth across segment
despit cut ep guidanc rang midpoint
specif area increment weak alarmingli broad-bas across
emerson portfolio like contribut stock sever
sell-off may vs peer full-year organ growth forecast
trim commerci
paus due volatil oil price short-cycl discret autom
deceler due excess distribut channel inventori built
ahead tariff/pric increas commerci on-going declin china
compound unexpect weak southeast asia
east collect segment mix mid-teen respons
new top-lin headwind emerson delay invest spend
acceler view modest mil restructur action
support unchang margin target cut
ep estim near low-end guidanc price target
hcv royalti line expect overal market share look
stabl slightli decreas long-term ex-u outlook partner
out-year mavyret revenu enrol complet ph ii rsv
challeng studi ph ii nash studi believ nt stock
focu shift bar success readout mid-year respect
believ studi show robust activ could provid clariti
pipelin potenti could lead greater investor focu asset
potenti upsid though given like take data fulli
understand promis differenti asset see risk/reward share
fairli balanc current level
report royalti hcv sale expect
follow earn suggest less ex-u wareh
revenu overal market share/pr look increasingli stabl slight
decreas hcv royalti off-set slightli lower run-rat pt chang
data rsv challeng studi variou dose regimen
expect mid-year anticip viral load declin vs placebo
coupl symptomat improv would indic activ
data nash studi expect third quarter
continu expect alt declin -- similar observ
week oca flint regener -- indic true clinic
effect improv threshold potenti suggest
valu usd unless otherwis note
est move higher better growth margin remain op
increas adj ebitda estim mm
driven higher expect revenu growth margin expans
volum solid go forward anticip favor organ growth
price prior forecast support share gain mix benefit
price/mix also lead increas margin forecast dynam
continu support de-lever remain outperform rais
price result increas adj ebitda est
beat fy estim move higher rais adj ebitda
mm mm in-lin mm guidanc driven
beat expect better organ growth recent cost
initi adj ebitda mm came ahead mm estim
driven higher revenu mm vs mm gm vs
partial off-set wors sg vs
rais revenu expect wallboard comp ration revenue
estimate move bn y/i organ bn
organ in-lin bn guidanc expect wallboard
revenu y/i mm vs mm prior driven organ
volum price vs prior mm
contribut prior mm ceil lower revenu estimate
y/i metal frame expect revenu grow y/i
margin increas price cost-out effort drive expans
adj ebitda margin estimate move bp y/i in-lin
guid increas gm forecast bp vs
prior higher price off-set inflat drive margin expans adj sg
estimate remain unchang bp y/i despit wors expect
vs
market data usd financi data usd dividend paid
omidubicel pivot track eye nk program updat
gmda continu maintain confid pipelin progress pivot
program key valu driver nicord name omidubicel track
readout early-stag nam-nk program provid earli ground
enthusiasm nam platform potenti ph updat expect
prospect inflect point under-the-radar program
trim pt updat reiter outperform
financi unev gmda end quarter cash
cash equival suffici though data readout pivot nicord
known omidubicel program expect gmda continu expect
cash use rang
pivot program omidubicel formerli known proprietari name nicord
still hum along manag reiter timelin larger pivot
valu usd unless otherwis note
program enrol track stick top line
ultim bla submiss success omidubicel core
driver valuat see potenti peak sale world-wide
gmda continu deliveri earli encourag data emerg
pipelin program fka nam-nk sever aplast anemia
quarter transplant cellular therapi meet
highlight potenti nicotinamide-bas cell expans technolog
initi effort compani build pipelin beyond later-stag
omidubicel pivot program gmda investig continu
plan toward fulli enrol patient singl site studi
high dose even balanc nhl mm patient goal report
updat data set potenti decemb
strong product perform leav us feel confid
margin profil compani like face global product volum
headwind neg mix shift diesel ga potenti higher
cost launch ahead stock intrigu hesit chase
amid poor backdrop auto pt revis forecast
review post solid strong product help mitig
impact global product declin neg mix shift ga turbo growth
diesel turbo declin buck margin trend see
guidanc reiter organ sale cadenc flat
manag indic organ declin met
intern expect impli organ sale roughli rbce
prod assumpt indic perform dictat
specif platform end sound like aid china european
launch activ manag indic europ fairli in-line
assum begin year though continu see downsid risk
european volum china appear count outperform
industri tie custom implement china emiss
intrigu part stori guidanc adj convers rate
rbce actual indemn
payment mtt lot optic headwind stori
leverag indemn payment despit cf solid manag
plan use pay debt big opportun would reduct
elimin indemn payment
outperform-r gate report oper miss weaker organ
sale unclear distributor destock north america given
sell-through remain rel healthi destock pressur back
gate form excess inventori take coupl quarter
work adjust ebitda guidanc cut
unexpect destock north american replac channel exacerb
anticip soft china europ first fit auto standout gate
unexpect distributor destock put bp pressur
organ sale surpris manag po data remain solid
distributor manag see clear explan channel
destock said gate taken signific oper action realign
product output inventori level prevail busi condit
cost near-term gross margin gate updat guidanc account
softer environ includ decreas adjust ebitda guidanc
mil midpoint reduc organ growth year
given share perform in-lin peer
last month would surpris see mid-single-digit percentag
pullback given weaker expect outlook due distributor
destock lower adjust ebitda estim mil
lower price target
valu usd unless otherwis note
headlin bill impact fx headwind underli busi remain
healthi continu product evolut intern growth fremium
multi-product adopt think guidanc year remain achievable/
beatabl number move margin pt
headlin calcul bill growth y/i y/i cc slightli
expect although think sub revenu growth larger rais
revenu beat given fx headwind increas
think underli busi remain healthi continu product evolut
intern growth fremium multi-product adopt
believ guidanc year remain achievable/beat number
move margin pt
valu usd unless otherwis note
solid cloud pampacancha delay
push mine pampacancha zone month took
price target otherwis major chang
model follow result rel return price target support
sector perform rate
push mine pampacancha zone month took
price target otherwis major
market data cad financi data usd
valu usd unless otherwis note
chang model follow result rel return price
target support sector perform rate
pampacancha surfac right come know believ
deal reach around surfac right pampacancha
signific amount money stake commun understand
hudbay patienc toward negoti unfortun latest chang
design requir addit govern consult cloud
time zone mine
explor could creat valu believ signific explor
potenti around constancia mine peru hudbay plan drill
target later
interest rosemont jv earli work underway rosemont process
sell interest manag believ strong interest acquir
stake calcul interest
cost continu creep manitoba combin mine/mil oper cost
believ cost
stabil lalor reach namepl capac
valuat appear attract trade estim vs peer
ebitda estim vs peer although
line hudbay histor discount peer
look window margin inflect
consist take last quarter estim revis cycl seem
stabil estim larg unchang solid north
american price trend eas cost inflat earli benefit global
cost reduct plan offset pocket soft demand heighten fx
headwind still anticip reacceler window busi
along greater clariti pace target mm benefit
oper improv initi mm restructur mm
jem benefit come quarter key said result like
remain challeng remain sector perform rais price target
tweak slightli lower mm mm adj ebitda move
mm mm pt base adj ebitda
translat ep
vpi higher price off-set softer core growth fx headwind
revenu estimate move slightli higher bn organ
bn organ midpoint guid total growth
estimate na volume/pric vs prior addit
anticip increment mm sale vpi acquisit contrast
lower outlook europ growth vs prior
australasia vs larg driven fx headwind estimate
increas bn organ bn
fx headwind lower volum curtail margin expans tweak
lower adj ebitda est expect
north america adj ebitda increas
australasia slightli vs prior contrast outlook europ
slip vs prior expect adj ebitda vs
valu usd unless otherwis note
set smooth
lp report result line consensu reiter
guidanc continu see upsid lp share due combin
grow side busi cyclic depress earn commod osb
attract valuat reiter top pick rate lower
price target base modestli lower ebitda forecast
louisiana-pacif report result line consensu reiter
guidanc continu see upsid lp share due combin
grow side busi cyclic depress earn commod osb
attract valuat reiter top pick rate lower
price target base modestli lower ebitda forecast
smooth smartsid cement lp spot us side market sinc
announc februari lp smooth smartsid strand product receiv
strong open order volum product momentum continu far
exceed manag expect believ smooth smartsid
product could disrupt us side market help lp take meaning
weatherlog get start sheath weatherlog repres
anoth opportun move valu chain commod osb
time manag believ good possibl sheath market
convert nearli weatherlogic-lik product time
manufactur effici rise lp announc plan gener
addit cash flow attribut expect
effici gain end lp realiz effici gain
quarter increas manag confid goal fulli
execut repurchas program accord manag
compani effect repurchas million share
outperform-r mueller report disappoint bad weather weaker
resi tragic workplac shoot contribut shortfal organ revenu
growth oper miss frankli didnt see anyth look like
execut misstep obvious extraneous/one-tim item
quarter also comfort pace invest technolog
weather weaker resi construct tragic workplac shoot
aurora il factori weigh result mueller report disappoint
oper miss broadli weak sale margin across
segment lower volum segment partial attribut weather
impact weaker expect resi construct workplac shoot
occur aurora il factori asid headwind
bright spot quarter price realiz off-set inflat
mueller believ close caught px/cost curv
go back cumul price impact close
cumul inflationari impact addit technolog organ growth
y/i book echolog busi double-digit
quarter continu expect quarterli result
reflect on-going invest new platform appreci trade-off
manag make lower ep estim introduc
estim reduc price target
valu usd unless otherwis note
valu usd unless otherwis note
investor frustrat justifi chang need lower price target
stock sell-off sent clear signal beyond manag
challeng forecast busi delay respond industri chang
govern frustrat contribut overli punit sell-off send share
back level struggl stock leav
rate unchang peer discount seem justifi pressur board
chang increas
lower ebitda billion billion billion ep
put new ev/ebitda
lower end group roughli point discount teva street confid
outlook like come fragil given top-lin uncertainti
low-end revenu rang seemingli unclear spend guidance/expect
inabl consist hit guidanc rang remain wide
leav expect low lower price target would still
meaning justifi discount group includ teva
understand capitul shorter-term focus
post-cal model updat reduc pt spend
updat model reflect report reduc kevzara
praluent estim result pt reduct new pt
model updat reflect report narrow financi guidanc
morn report in-lin eylea vs st
miss bottom-lin estim driven primarili increas cost contract
manufactur cocm lower reimburs sanofi sni
higher spend early-stag pipelin link first blush note
valu usd unless otherwis note
valu usd unless otherwis note
sg saw increas headcount spend increas patient assist
least portion latter like larg limit
contract manufactur cocm expens increas due process
valid limerick manufactur facil addit higher write-
off reserv look color call detail potenti batch/
lot failur eylea batch variabl continu somewhat linger
physician/investor concern follow inflamm tie sever batch
eylea though thought link suppli needl link
data bispecif antibodi eha well
get updat on-going trial non-hodgkin lymphoma follicular
lymphoma diffus larg b-cell lymphoma data present
link note competit plan initi potenti
registr trial fl dlbcl quarter later year
gain traction valuat keep us sp
encourag terminix organ revenu growth improv
oper metric suggest on-going initi work
miss big move maintain sp rate due valuat could look
get construct pullback
 upsid evid continu traction
terminix resi transform ahead see similar opportun
commerci categori lag net lot like progress
seem match posit feedback recent pest control survey
rais estim price target maintain sp primarili reflect
valuat share fairli full rel peer group pest peer
revenue org vs adj ebitda
top our/con includ benefit relat favor
claim result off-set dis-synergi drag invest
expect terminix revenue organ vs incl weather
drag vs y/i org con pest organ
termit organ comml flat inorgan growth driven acq
copesan assur ebitda margin y/i top
smb revenue y/i met estimate benefit strength natl
y/i top
reiter outlook y/i adj ebitda
vs con incl dis-synergi terminix org
revenue underli increment ebitda margin smb organ msd
margin mix dis-synergi
attract entri point fundament still solid
valu usd unless otherwis note
valu usd unless otherwis note
think share impact noisi quarter near-term issu
trade attract valuat fundament remain rel firm
expect phosphat market improv moder slide
potash price like alreadi price share view brazil tail issu
temporari execut key complet necessari work mine re-
valuat trade near histor low downsid support attract entri
point usual hesit make call valuat current
valuat may except ev/ebitda trade near histor low current
ev/ebitda estim vs averag low
yield estim although posit
catalyst may requir push share higher brazil op updat phosphate/
potash price crop price time uncertain think current valuat
provid downsid support attract entri point
phosphat market expect improv although phosphat market
perform expect past due slow
demand new capac expect demand improv
continu see indic remain construct phosphat strip margin
remain near averag despit weak market condit ammonia
despit attract margin pho rock acid price held well
chines pho export increas rel minor rel overal market
brazil mine shut-down remain overhang consid temporari issu
stress issu addit cost larg temporari
mostli revers addit compani continu work
realiz synergi fertilizant busi posit
scratch surfac signific opportun
investor day reinforc invest thesi highlight
opportun compel lt growth
simpli put right team right strategi place capit
despit rais guidanc result believ good
chanc guidanc could prove conserv base current momentum
busi better retent like increas ltv better prepar
flex staf next next benefit target effort drive
given pend acquisit tranzact
revenu think rel valuat attract
maintain outperform rate base
 anoth beat rais
valu usd unless otherwis note
valu usd unless otherwis note
revenu forecast consensu report
revenu rbce vs fce increas
y/i report basi sequenti
manag rais revenu guidanc consensu rais
revenu guidanc prior vs fce
rbce increas y/i
call irtc spent larg portion prepar remark cover
reimburs transit categori categori code
specialti societi sponsor code convers also
offici advisori seat committe work collabor
code chang applic order effect
sponsor code chang app need industri advisor
sinc leader space manag expect code chang
occur earlier later regard reimburs
manag reiter anticip substanti chang
anoth beat rais expect share move higher irtc stock
controversi late stock high
ytd believ zio long runway current
test per year penetr room expans test per
year new indic asymptomat af patient
stronger expect project track
overal expect posit respons kinrosss report report
adjust earn consensu estim stronger
expect oper result across sever asset oper capital-expenditure
guidanc reiter develop project track kinross
report adj ep includ cost associ
ft knox pit wall slide would result adj ep well rbce
consensu varianc estim due stronger oper
result lower depreci pre-wc lever cfp rbce
consensu higher forecast tax interest paid
strong oper result attribut gold equival product
koz rbce koz cost sale rbce aisc
oz rbce product exceed forecast paracatu maricunga
kupol tasiast partial off-set weaker product ft knox
project track nevada bald mountain vantag process facil
commiss schedul ore place new leach
pad expect capit cost vs initi budget
round mountain phase expans budget/schedul ore
place new leach pad
 peripher vascular next leg growth
report solid start year report revenu
rbce vs fce increas y/i constant currenc
cc sequenti
peripher vascular neurovascular grew double-digit y/i pen
peripher vascular revenu rbce vs fce
increas y/i trail twelv month peripher vascular grown
impress pen neurovascular sale stroke coil etc
valu usd unless otherwis note
valu usd unless otherwis note
rbce vs fce increas y/i constant
learn earn call reiter revenu
guidanc rbce vs fce despit beat
consensu although compani formal rais revenu
guid manag feel comfort toward top end slightli
top end initi rang first time manag use
guid languag separ manag believ possibl expand
 peripher thrombectomi beyond initi patient pen
market share moreov manag highlight immers
recent fda approv product assist stroke rehab patient
virtual realiti set competit front yet see chang
competit activ havent seen past year final
manag typic keep tight lid new product develop howev
sens alreadi develop next aspir cathet
suppli logist drive big beat increas guidanc
well expect paa report adjust ebitda
our/consensu estim gener
dcf our/consensu estim
beat due mainli unhedg portion paa volum
benefit region basi differenti expect paa outperform
amz tomorrow strong beat guidanc increas though much
like due perform
profit estim facil segment profit
paa report adjust profit estim suppli
 logist segment profit paa report adjust profit well
estim
takeaway call caplin open season close today partner
evalu potenti revers paa capital-expenditure includ revers cost
paa final shipper agreement expand red river assum red
river expans caplin reversal/diamond expans paa would expect
increment capital-expenditure spend
paa continu market wink webster pipelin third-parti shipper
would consid addit equiti partner project
attend ptct analyst event featur sma physician talk
perspect emerg data
key consider potenti choos risdiplam spinraza
risdiplam efficaci impress even efficaci safeti quit
spinraza benefit long safeti experi impress pre-symptomat
data zolgensma uptak may depend initi label reimburs
come event chang view ptct/roch
risdiplam could captur signific futur share type market
sale potenti royalti opportun
valu usd unless otherwis note
valu usd unless otherwis note
zilu gmg data look good add valid durabl prior updat
zilucoplan gmg updat valid durabl
placebo crossov open-label extens valid prior efficaci
zilu safeti remain clean morn american academi neurolog
meet rarx present updat data phase studi
zilucoplan zilu gmg updat durabl vs prior
placebo crossov valid initi data announc rarx see
note zilu safeti remain clean seriou advers event sae
complement inhibition-rel meningococc infect
zilucoplan outperform chosen go-
forward dose zilu saw improv clinic qualiti
life qol efficaci measur time across gmg endpoint measur
includ wet shave bp deceler sequenti averag
basi previous written fulli expect epc top-lin challeng
continu importantli see downward revis ep absent
divestitur given cost save momentum look forward hear new
cfo sullivan well updat feminin divestitur time
what bake guidanc much wet shave disrupt notic
well anticip fulli bake current guidanc includ
harri continu ramp well flamingo launch
stepped-up gillett promot costco purchas
one area uncertain gs exclus launch joy
lower-pr femal blade/razor rod littl factor
understand rod effect tighten compani forecast
process effect non-exist previous rod also
effect inspir motiv employe anoth factor arguabl
valu usd unless otherwis note
valu usd unless otherwis note
lack organ importantli mr littl made key hire sinc
take ceo includ hire new cfo sullivan well new
head market north america
also ahead consensu expect step reinvest behind
market quarter drove acceler sale growth despit weather
concern continu mediocr brewer sale
look quarter brewer still lead indic
brewer result declin due part shift purchas among retail
brewer sale also impact discontinu select
legaci brewer off-set new innov expect brewer fair better
standout point actual brewer growth less
import compon stori look forward brewer qualiti improv
custom hold brewer longer return purchas
high brewer instal base pod growth come investor focu
convict pod grow despit brewer sale slow quarterli
flow volatil quarter highest
cog inflat year product synergi ramp
year lower ep growth due part gain
year ago includ seri new innov oper incom
disloc ep year dp trend weather challeng
overal beverag categori though accord iri dp beverag
across categori bp acceler look
forward new product canada dri ginger lemonad diet well
ginger orang aid expect well
base model sensit work believ street estim
reason greater probabl upsid vs downsid varianc revenu
given compani consist track record out-performance vs guidanc
wix report result may market open forecast
revenu free revenu less
consensu high end guidanc modestli
consensu also forecast collect line
street manag guidanc view
street assumpt reason would expect guidanc like
bracket term guid would expect wix either repeat
modestli rais guid
wix current test packag enterpris includ wix code design
seo secur code review person support agent believ test
widespread could cost much per month materi
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
higher annual revenu per pay sub packag
like target small portion user believ
potenti offer continu open wix acquisit upsel funnel
top custom demonstr potenti valu corvid wix code could
unlock expect materi number look
forward hear test ep call wix code
corvid
item focu aqrp collect net new user sub
solid start improv ss top-line growth
result continu support thesi reflect solid organ
growth attract pipelin acceler long-term opportun
addu deliv anoth solid quarter improv organ growth short-
term headwind abat contribut recent acquisit
manag remain confid organ growth target
balanc sheet remain solid low leverag strong access capit
fund activ
look compani see increas interest medicar
advantag plan appear like ramp offer person care
servic provid scale well posit
capit opportun
declin custom attrition/revenu payback good free cash flow
posit consist roadmap meanwhil recent refinanc
improv capit structur like evolv model see favor risk/
maintain outperform upsid ebitda benefit improv metric
lower custom attrit revenu payback balanc remain
construct attract valuat rise free cash support growth
highlight y/i ex red hawk top our/con
y/ incl red hawk core resi/comm offset declin canadian
biz ltm gross revenu attrit y/i payback y/i
guid maintain includ adj ebitda bracket our/
consensu revenu still vs our/con
valu usd unless otherwis note
gross custom revenu attrit still expect item
improv balanc includ grow commerci platform new/
adjust est ebitda essenti unchang
revenu pt remain
macro fundament backdrop intact fuel strong growth
deliv healthi earn report despit modest headlin miss
rel estim consensu oper perform gener
bounc around quarter quarter even full-year result
still expect in-plac portfolio gener organ growth invest
drive signific extern growth total deliv ffo growth
report ffo miss estim consensu
howev due recent acquisit activ increas
estim addit maintain
estim respect
lower normal same-stor noi run-rat mainli driven
time differ relat work comp spike fall late april
believ full-year perform still within long-term rang
manag activ ytd commit deploy billion
capit includ cloverleaf linear acquisit believ
remain activ pursu deal along develop expans
opportun given custom current space requir
balanc sheet lowli lever pro-forma net debt ebitda ratio
well long-term target estim
manag million debt/cash capac leverag would
even hit low end rang
buckl charg clinic potenti first data
apto increment though meaning step advanc clinical-stag
oncolog portfolio two well-differenti small molecul continu
radar though key asset first dose potenti cours first
patient data year-end see opportun upsid reiter outperform
financi unev apto end quarter cash
cash equival combin apto avail sourc capit
provid fund runway
apto continu take right step propel earli high-potenti
program clinic measur road de-risk look
forward eye continu point goal initi data
market data usd financi data usd dividend paid
valu usd unless otherwis note
apto novel oral inhibitor still await first patient dose
set stage eagerli anticip collect b-cell
patient break right
believ hold attract versatil market potenti given
uniqu inhibit properti across aml b-cell cancer popul
howev patient experi apto clinic plan remain ultim test
size prospect
return clinic continu show sign success second dose
level achiev iv myc inhibitor progress well second
patient md disclos second dose level expect dose
escal continu interest ultim increment
result balanc good market driven gain support strong
annuiti result although life run-off result lag announc buy-back
meaning accret earn book valu view
posit expect signific re-rat near-term said
long-term progress emerg patienc abil ride
estim price target revis ep estim increas
ep estim move estim
larg chang result increment buy-back program expect
accret earn book valu per share addit made
sever small chang annuiti life unit assumpt
price target per share unchang continu base
end book valu estim
result brighthous report adjust oper incom per
share vs per share year-ago quarter estim
per share notabl item quarter net million unfavor
includ adjust oper earn exclud item
normal basi oper ep like closer beat
compar estim consensu
higher expect life benefit ratio lag altern
stick
deliv slightli better expect quarter bias model
toward upper-end product guidanc current valuat look attract
think investor want see anoth quarter progress
stabil oil price
effici better product drive perform upper wolfcamp well
perform averag track ahead averag ahead
valu usd unless otherwis note
valu usd unless otherwis note
intern typecurv like larg function conservat
view capit spend in-lin estim despit slightli acceler
facil spend pre-build infrastructur futur develop think
well perform coupl improv effici posit
compani meet exceed product guid bias capit spend
lower compani maintain complet guidanc product
forecast increas mboe/d mb/d oil strong perform
improv effici
chang outlook reiter commit flexibl
manag activ oil price environ support potenti
increas activ continu oper effici gain allow
compani oper slightli ahead plan maintain budget see
higher potenti activ increas oil price stabil
firm macro backdrop remain commit maintain conserv
balanc sheet state net-debt/book cap toler rang slightli increas
previous maintain six rig oper outlook
inventori replac manag believ pace replac
inventori year
solid trend push result near top end full-year ffo outlook
remain encourag compani near-term growth prospect expect
quarterli ffo result trend higher next quarter share also
pay attract dividend yield underfund today expect
cover maintain outperform rate
increas report company-defin ffo estim
share lower estim
share introduc estim
store portfolio gener cash noi growth quarter
manag expect result acceler toward top end full-
year forecast
manag activ deploy capit complet agre
complet million acquisit year-to-d given current cost
capit expect invest activ moder improv
estim pro-forma net debt ebitda ratio given
expect invest activ metric like increas modestli
next quarter
opportun meet wheat cfo jessica hansen ir
earlier week dalla takeaway
strike posit balanc tone spring manag character
spring demand environ good exuber regard recent
downshift top-lin goal vs prior aspir management discuss view
valu usd unless otherwis note
current environ cost achiev double-digit revenu growth
high compani pleas abil begin claw back
heavier incent use late last year care price
standpoint focu continu afford constraint
new under-penetr market key growth focu go forward
achiev above-market growth like increasingli depend
expand new market deepen posit dhi local share
current less domin said futur like resembl recent
throttl back spec one curiou thing recent permit activ
typic good indic demand/confid remain weak despit
optimist tone compani order trend less-bad-than-fear
note continu adjust product level match demand
plan reduc spec level back flat y/i year-end unless market
rebound meaning expect may see near-term spring-
back permit activ
play long game balanc sheet manag compani
reiter balanc sheet/capit deploy object note plan
continu reduc net leverag come year buy-back program like
continu expand modestli time
volum challeng persist dmg sale look closer
softer volum lack clariti calcimimet could weigh share
optim dmg divestitur provid hope
near-term outlook somewhat cloud non-acquir treatment
growth trend reduc outlook tailwind
calcimimet drove upsid vs management expect could becom
headwind later year although time clear
said dmg divestitur appear closer complet combin
strong cfop enabl signific buyback
valu usd unless otherwis note
pipelin updat move forward focu
report came posit nerv agent studi result sever
pipelin updat set sever updat come call focu
intern pipelin progress focu busi develop remain
sever opportun evalu host confer
may chang target leav quarter
valu usd unless otherwis note
valu usd unless otherwis note
meet upcom investors/w given limit credit expans
model continu invest heavili behind greater
visibl fda post meet may potenti help bolster confid
manag meet agenc june around path forward
exert heat stroke eh expect remain low follow
posit nerv agent data releas concurr plan meet
fda around path forward also new intramuscular formul im
move forward approv could grant year nce exclus
acut radiat syndrom ar indic develop anticip
im form compani also expect disclos least one
indic ryanodex near futur
continu strength behind bendamustin franchis give support
pursu busi develop expect focu continu pick
revis bendeka deal well belrapzo bag j-code win provid
help cash flow near-term visibl said activ
evalu busi develop opportun time today
call indic yet find perfect asset compani expect
remain activ evalu potenti in-licens opportun expect
greater visibl fda feedback around pipelin product inform
level urgenc
strong track record execut reiter op
energ core busi integr spectrum batteri auto care
busi track line expect thu far acknowledg investor
concern gross margin asset integr believ manag deliv
state ebitda ep guidanc rang reiter outperform
gross margin pressur sourc futur upsid
acknowledg near-term investor concern around compani guidanc
gross margin contract bp mid-point vs consensu
howev gross margin pressur result lower
margin acquir busi near-term energ deliv valu
creation revenu growth ebit margin via synergi long-term
believ get gross margin pre-acquisit level achiev
key valu driver year
batteri price distribut gain continu look forward long-
term wonder mix becom major third pillar organ growth trade
rayovac energ incentiv well manag trade optim
innov plan ultim energ tool continu
prove success strategi help retail grow batteri
adjust estim maintain ep estim
updat guidanc call organ growth
driven price alreadi execut retail distribut gain updat
guidanc
valu usd unless otherwis note
valu usd unless otherwis note
nda re-submiss time slip plan otherwis remain track
report came modest delay lead product amphora
push key approv catalyst next year done right reason
better posit amphora launch importantli phase sti studi ou
partner discuss remain track moreov recent financ place
better financi posit chang outlook price target
plan re-submit nda effect amount
delay previous plan follow compani
recent type meet fda open door expedit rout
includ addit manufactur site nda mean
better posit suppli market scale upon launch
take time gener addit stabil data result delay
compani continu expect six-month review would place approv
updat model push amphora launch
along relat commerci spend howev
make chang peak sale estim price target stay unchang
acceler invest trend drive better long-term growth
hcp done good job past year reposit portfolio
simplifi strategi compani posit aggress
deploy capit drive better long-term growth manag alreadi
achiev initi invest goal note advanc discuss
addit opportun rate target unchang
lower report company-defin ffo estim
respect
also introduc expect
manag aggress pursu new acquisitions/
develop deal either drove increment earn accret
and/or improv qualiti in-plac portfolio
compani near end portfolio reposit strategi sold
billion asset sinc process simplifi
stori transit sunris leas oakmont leas commun
oper portfolio
estim pro-forma net debt ebitda ratio assum
announc acquisit forward equiti agreement howev
expect metric increas manag builds-out
in-lin result wait back half
ichor report in-lin result jun-qtr guidanc bit
expect think set beyond remain larg unchang
valu usd unless otherwis note
valu usd unless otherwis note
see wfe recov believ posit upsid
data center smartphon drive memori growth exit year
take-away mar-qtr result in-lin guidanc lighter
street expect unsurpris given lighter expect micron semi-
cap result q/q basi posit commentari set
appear larg unchang like notabl year
ichor talk around talk low point think
focu ichor turn comment demand ichor
abil look increment tuck-in acquisit valuat come
net net jun-qtr guid light think investor look
past bump along memori bottom wait data center
smartphon demand ramp back despit number adjust
ftm price-to-earnings valuat remain unchang lead us price target
clean quarter littl debat xyrem life-cycle need remain
brought littl surpris welcom repriev otherwis
volatil day sector guidanc re-affirmed pipelin on-track major
driver stock go quarter still leav overal
result taken well particularli given call notabl
neg sentiment around name recent month chang target
came across revenu line full-year guidanc re-affirmed said
sizabl part beat better-than-expect erwinaz revenu driven
temporari improv suppli expect suppli constraint
sporad balanc year xyrem trend remain solid
bottl growth bolster pediatr label expans
launch march vyxeo deliv share headwind
launch up-tak also came modestli street though much
sequenti growth attribut european launch bottom line overal solid
quarter without surpris larg expect upsid come
xyrem life-cycl potenti busi develop aim
diversifi busi approach new ev/
ebitda clean balanc sheet flexibl deal expect focu
remain high deal
upcom sunosi launch import catalyst appropri get
lot focu sunosi launch next near-term catalyst host call
closer mid-year launch discuss launch strategi detail
larg line transit continu takeout headlin emerg
post larg in-lin quarter bank segment show sign
strength overal product gain emerg retail hospit
valu usd unless otherwis note
valu usd unless otherwis note
segment still tri find groov tweak estim maintain
target reiter top pick
result report adjust ep wors
estim street revenu constant
transit continu march higher recur revenu
case last quarter question atm demand answer strong
growth y/i cc growth driven window upgrad
cycl act tailwind new sale compani seri
recur revenu increas y/i cc repres total
revenu direct encourag
potenti transact confer call manag address
comment today bloomberg articl report compani hire
strateg advisor could pursu sale compani estim
could worth per share base preliminari sum
part segment
tweak estim reiter target price top pick rate guidanc
re-affirmed modestli adjust estim close align
manag guidanc specif take
adjust ep respect given
modest adjust ep maintain target price
roughli ep
report bracket ep result revenu ebitda
street est high-end compani guidanc revenu guidanc tad
street mid-point ebitda guidanc bracket street
high-end management reiter fy guidanc tweak estim keep pt
revenu y/i came rbc/street
ebitda margin also came rbc/street estim
soft promot spend persist
three cpg affect quot resultshad spend remain flat y/i
total revenu would grown y/i manag guidanc
bracket street estim compani reiter fy guid
fundament trend negativerevenu growth deceler y/
q/q ebitda margin contract pt y/i
review model updat
valu usd unless otherwis note
valu usd unless otherwis note
revenu ebitda better estim wireless metric mix
manag provid formal guidanc though oper trend
remain pressur headwind new account standard drive
summari sprint report solid financi result revenue/adj
ebitda consensu wireless result mix wireless
revenue/adj ebitda came consensu modest miss
servic revenu off-set strength equip sales/rent
swing factor estim chang formal guidanc
provid though manag expect postpaid phone gross add
slightli lower sequenti given seasonality/competit intens churn
y/i sequenti improv reflect season similar
postpaid phone custom loss pressur postpaid servic revenu
total wireless servic revenu y/i due
account chang adj ebitda y/i given
wireless servic revenu pressur non-cash account headwind cost
pressur materi chang current capital-expenditure level cash capital-expenditure
similar previous provid outlook
break-even reiter manag instead point
focu liquid posit current revenue/ebitda
forecast move estim
move
posit intra-day swing coincid management commentari new
project scrutini hurdl higher see less
probabl buyer minor interest west tx midland system
commentari mesh better market prefer capit disciplin
think pois grow ebitda amid moder capital-expenditure reiter
result report ebitda street
estim estim miss
estim due part higher opex expect per-unit opex metric
improv next year hire ahead system
fulli ramp dcf provid coverag quarterli
distribut total prefer dividend
result expect speedpay sale creat nois
wu report revenu oper profit ep expect
speedpay paymap divestitur dilut result
valu usd unless otherwis note
valu usd unless otherwis note
result report revenu
y/i constant currenc versu respect last quarter
revenu forecast fx act
headwind versu headwind last quarter oper incom
forecast oper margin versu
forecast last year
asset sale month western union complet previous
announc sale us domest bill payment busi speedpay
cash addit compani complet sale paymap transact
accord compani dilut ep
adjust ep estim maintain target price given result guidanc
inclus effect asset sale increas ep
estim inclus gain sale tax revalu
reduc ep estim mainli dilut
effect asset sale despit decreas forward estim
maintain target price ep roughli line
share histor averag multipl think appropri given
forecast modest ep growth adjust gain sale
ffo trend stabil larg deal could provid step-up
encourag progress made past quarter
particularli resolv triple-net leas tight coverag ratio
manag abl focu growth initi includ advanc
sizeabl develop pipelin pursu new acquisit opportun
expect earn trend stabil improv
rate target unchang
reiter report ffo estim
respect introduc estim
expect invest trend could acceler better posit
arm better cost capit aggress sourc
noi tripl net leas ebitdarm
coverag ratio howev manag resolv
process resolv problem
pro-forma net debt ebitda ratio rest well within
target rang billion debt capac fund
 wide open space room grow sub
continu encourag wow execut improv ebitda
trajectori given solid hsd sub trend scope oper effici
robust opportun ahead edge-out busi servic howev
remain sidelin think investor need see meaning
ramp support de-lever effort current beyond potenti
annual reduct mid-singl digit ebitda growth
valu usd unless otherwis note
valu usd unless otherwis note
in-lin estim adj ebitda grew y/i
rbc/consensu reflect
bp margin upsid bp y/i manag reiter
guidanc includ total revenu transact adj ebitda
includ y/i growth year transact adj capital-expenditure
posit estim larg unchang
mid-point guidanc
subscrib trend remain solid hsd net add organ
rbc/consensu manag reiter expect
net add full-year video net loss rel
in-lin compar rbc/consensu sub churn best
quarter last two year despit annual rate increas
implement februari compar april sub growth
expect given price increas anticip uptick
move-rel custom churn typic competit pressur relat
custom acquisit appear stabl though seen pressur
competitor take stronger stanc retent effort
continu strong busi momentum shoulder highlight
confid wmgi robust end-market new product special
sale forc fuel continu double-digit revenu growth next sever
year moreov remain believ strateg rational cartiva deal
success deal integr key drive share out-performance
revenu adjust ebitda consensu report
revenu fce y/i constant currenc rbce
y/i exclud cartiva rbce separ manag
report non-gaap adjust ebitda rbce fce
non-gaap rbce fce
revenu beat driven upper extrem biolog wmgi
upper extrem revenu y/i rbce strength
due perform revers glenoid simplic stemless shoulder
addit blueprint drive new surgeon convers new
surgeon custom ad highest ever
lower extrem revenu y/i rbce
y/i exclud cartiva rbce biolog revenu
y/i constant currenc rbce biolog revenu beat driven
bulk order pdgf raw materi
underli busi momentum remain strong play
faster-grow market within orthoped extrem still grow high-
singl digit y/i expect compani remain share gainer
 shoulder market owe continu blueprint simplic adopt
well upcom launch reviv revis shoulder system
lower extrem expect take share highli differenti
implant cartiva synthet cartilag surgic techniqu prostep mi
valu usd unless otherwis note
valu usd unless otherwis note
outlook
result remain strong stabl core fundament loan growth
remain posit fed paus becom primari driver
earn growth outlook gener consist though modestli
lower estim maintain favor stanc prefer
driven name differenti growth outlook margin expans
expect fade favorit
also favor name gener consist result
profit remain strong median roa median roe
median ep increas sequenti year-
margin stabl median
loan growth remain posit quarter median total loan growth
compar prior quarter
median fee incom increas sequenti good
perform median expens increas sequenti
solid credit trend continu provis level charge-off remain low
like see modestli higher provis normal charge-off
modestli higher reserv due loan growth
saw strong result rel expect
accord anfavea brazil lv registr y/i april month
improv revers march declin first monthli y/i decreas
sinc april automak fca volkswagen gm hyundai
greatest outperform registr y/i y/i
y/i y/i respect mercedes-benz nissan renault
largest underperform declin y/i y/i y/i
respect gm market share m/m
y/i market share m/m y/i april
first month experienc m/m market share gain year
market highlight mine share fall tariff talk us china
mine share last week continu fall start week
trade tension us presid trump threaten rais tariff friday
week us offici said china backtrack commit made
trade talk talk expect continu thursday friday
week look comment either side progress toward deal
potenti tariff fallout
copper last week inventori climb
compound neg macro sentiment copper inventori rose long
posit decreas push copper price back
probabl arent far find floor believ copper support
rang assum china/u talk dont complet derail
number long posit copper contract decreas past week fall
contract contract
valu usd unless otherwis note
valu gbp unless otherwis note
valu usd unless otherwis note
coal flat last week shorten week seaborn coke
coal flat quiet week trade chines market close
labor day holiday
ore last week anoth week tuesday
mine share trade premium forward curv
pictur week volume
zero bolt pepsico gatorad situat
bodi armor cut gatorad emerg bodi armor put
signific pressur gatorad brand accord iri gatorad volum
share sport drink bp latest four week end
compar bodi armor bp expect bodi armor pressur
gatorad increas brand get emphasi within system
estim gatorad current point distribut
bodi armor expect gap close come year channel
work also suggest gatorad also pressur peripher product
blur categori line pedialyt
gatorad zero bolt effort improv market share
momentum launch gatorad zero june iri data suggest
total gatorad portfolio return growth latest four
week end entir driven zero gatorad zero contribut
pt core pt drag wonder gatorad zero
perform lap origin launch one thing could aid
compani upcom launch new sport drink august plan
launch bolt natur flavors/sweet contain less sugar
core gatorad use watermelon sea salt sodium bolt
launch c-store august
unip reject activist investor call spin russian arm
intern of daili
dno dno ol net debt beat post faro acquisit come parex
resourc pxt solid balanc sheet steadi product growth
test result aker bp follow barrel global oil trade
scorecard strip nois focus physic barrel
follow barrel global oil trade scorecard
strip nois focus physic barrel
valu usd unless otherwis note
fluid natur market make static suppli demand model overli
simplist way analyz dynam oil market public aim
strip nois focu global physic flow ascertain whether
fundament tighten loosen
foreign polici crude qualiti issu rewrit think global
oil flow atlant basin differenti contamin russian oil saudi osp
among other bullish physic driver left venezuela iran
other fill pace chines import dictat
degre tight global market
despit recent price weak contend global fundament remain
strong punctuat firm brent spread despit volatil spot price clear
sign profit-tak otherwis strong physic market
global balanc tight north american balanc sloppi dynam
two region interact determin whether fundament
improv barrel difficulti place us export arbitrag
current close mani destin current us product like higher
market realiz given import/export data along refineri run
justifi recent larg stock build
what style highlight best-rank stock p/tsx composit
base valu growth momentum predict style-composit
includ four summari tabl present report select
fundament metric forward look price-to-earn price-to-book
addit indic given compani rank top posit
index base one invest disciplin
attend afternoon session updat data across
development sma therapeut finish
new chop-intend data lend clear addit support roche/ptct
risdiplam opportun type
long-term follow-up data look impress patient
aliv free perman ventil march
believ new analysi sunfish studi support clear meaning
activ risiplam among type patient
capit market busi name use certain branch subsidiari royal bank canada includ dominion secur inc
capit market llc europ limit royal bank canada hong kong branch royal bank canada sydney branch inform contain
report compil capit market sourc believ reliabl represent warranti express impli made royal
canada capit market affili person accuraci complet correct opinion estim contain
report constitut capit market judgement date report subject chang without notic provid good faith without
legal respons noth report constitut legal account tax advic individu tailor invest advic materi prepar gener
circul client prepar without regard individu financi circumst object person receiv invest
servic contain report may suitabl recommend consult independ invest advisor doubt
suitabl invest servic report offer sell solicit offer buy secur past perform guid
futur perform futur return guarante loss origin capit may occur capit market research analyst compens base
part overal profit capit market includ profit attribut invest bank revenu everi provinc canada state
 countri throughout world law regul type secur invest product may offer
resid well process result secur discuss report may elig sale jurisdict
capit market may restrict publish research report time time due regulatori restrict and/ intern complianc polici
case latest publish research report avail client may reflect recent materi chang applic industri and/or applic subject
compani capit market research report current date set forth research report report circumst
constru solicit act secur broker dealer jurisdict person compani legal permit carri
busi secur broker dealer jurisdict full extent permit law neither capit market affili
person accept liabil whatsoev direct consequenti loss aris use report inform contain herein matter
contain document may reproduc copi mean without prior consent capit market
addit inform avail request
public approv capit market llc member finra nyse sipc regist broker-deal accept
respons report dissemin unit state recipi report regist broker-deal bank act
broker dealer capac wish inform regard effect transact secur discuss report
contact place order capit market llc
public approv dominion secur inc member iiroc canadian recipi report design institut
ontario accredit investor british columbia alberta sophist purchas quebec similar permit purchas provinc
wish inform regard effect transact secur discuss report contact place order
dominion secur inc without way limit forego accept respons report dissemin canada
public approv europ limit el author prudenti regul author regul
conduct author fca prudenti regul author connect distribut unit kingdom materi gener
distribut unit kingdom retail client defin rule fca rbcel accept respons report dissemin
unit kingdom
materi distribut germani europ limit frankfurt branch regul bundesanstalt fr finanzdienstleistungsaufsicht bafin
receiv advic australia
materi distribut australia royal bank canada sydney branch abn afsl materi prepar
gener circul take account object financi situat need recipi accordingli recipi act
materi consid appropri materi regard object financi situat need materi relat acquisit
possibl acquisit particular financi product recipi australia obtain relev disclosur document prepar respect product
